Condition
Radioiodine Refractory Differentiated Thyroid Cancer clinical trials and research
Research outlook What's coming for Thyroid cancer: the next 6 months to 5 yearsAs of November 12, 2026, Find a Trial lists 2 Radioiodine Refractory Differentiated Thyroid Cancer clinical trials that are recruiting, in China. By phase: Early Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 2Clinical trials
- 1Country
All recruiting trials (2)
-
Sacituzumab tirumotecan with or without tislelizumab for advanced thyroid cancer
This trial tests sacituzumab tirumotecan, given alone or together with the immunotherapy tislelizumab, in adults with unresectable or metastatic anaplastic, poorly differentiated, or radioactive iodine‑refractory differentiated thyroid cancer to see if it slows disease or improves survival.
-
177Lu-LNC1004 Injection for treating advanced thyroid cancer
This study is testing a new injection for advanced thyroid cancer to see if it can help patients who haven't responded to other treatments.
Related topics
Quick answers
How many Radioiodine Refractory Differentiated Thyroid Cancer clinical trials are recruiting right now?
2, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Early Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.